-
1
-
-
77952118055
-
-
European Medicines Evaluation Agency Available at:. Accessed April 19, 2011
-
European Medicines Evaluation Agency. Omalizumab (XOLAIR). Summary of product characteristics. Available at: www.ema.europa.eu. Accessed April 19, 2011.
-
Omalizumab (XOLAIR). Summary of Product Characteristics
-
-
-
2
-
-
84876873428
-
-
Novartis US and Genentech Available at:. Accessed June 26, 2010
-
Novartis US and Genentech. Omalizumab (Xolair) label. Available at: www.gene.com. Accessed June 26, 2010.
-
Omalizumab (Xolair) Label
-
-
-
3
-
-
0034907372
-
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
-
W. Busse, J. Corren, B.Q. Lanier, M. McAlary, A. Fowler-Taylor, and G.D. Cioppa Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma J Allergy Clin Immunol 108 2001 184 190
-
(2001)
J Allergy Clin Immunol
, vol.108
, pp. 184-190
-
-
Busse, W.1
Corren, J.2
Lanier, B.Q.3
McAlary, M.4
Fowler-Taylor, A.5
Cioppa, G.D.6
-
4
-
-
0029076544
-
Inhibition of allergic reactions with antibodies to IgE
-
R.L. Shields, W.R. Whether, K. Zioncheck, L. O'Connell, B. Fendly, and L.G. Presta Inhibition of allergic reactions with antibodies to IgE Int Arch Allergy Immunol 107 1995 308 312
-
(1995)
Int Arch Allergy Immunol
, vol.107
, pp. 308-312
-
-
Shields, R.L.1
Whether, W.R.2
Zioncheck, K.3
O'Connell, L.4
Fendly, B.5
Presta, L.G.6
-
5
-
-
0027244256
-
Humanization of an antibody directed against IgE
-
L.G. Presta, S.J. Lahr, R.L. Shields, J.P. Porter, C.M. Gorman, and B.M. Fendly Humanization of an antibody directed against IgE J Immunol 151 1993 2623 2632
-
(1993)
J Immunol
, vol.151
, pp. 2623-2632
-
-
Presta, L.G.1
Lahr, S.J.2
Shields, R.L.3
Porter, J.P.4
Gorman, C.M.5
Fendly, B.M.6
-
6
-
-
1242341925
-
Anti-IgE monoclonal antibody, omalizumab: A new treatment for allergic asthma
-
K.F. Chung Anti-IgE monoclonal antibody, omalizumab: a new treatment for allergic asthma Expert Opin Pharmacother 5 2004 439 446
-
(2004)
Expert Opin Pharmacother
, vol.5
, pp. 439-446
-
-
Chung, K.F.1
-
7
-
-
77955487167
-
Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update
-
G. D'Amato, M. Perticone, E. Bucchioni, A. Salzillo, M. D'Amato, and G. Liccardi Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update Eur Ann Allergy Clin Immunol 42 2010 135 140
-
(2010)
Eur Ann Allergy Clin Immunol
, vol.42
, pp. 135-140
-
-
D'Amato, G.1
Perticone, M.2
Bucchioni, E.3
Salzillo, A.4
D'Amato, M.5
Liccardi, G.6
-
8
-
-
0035262324
-
Anti-immunoglobulin e for the treatment of allergic disease
-
W. Busse, and W. Neaville Anti-immunoglobulin E for the treatment of allergic disease Curr Opin Allergy Clin Immunol 1 2001 105 108
-
(2001)
Curr Opin Allergy Clin Immunol
, vol.1
, pp. 105-108
-
-
Busse, W.1
Neaville, W.2
-
9
-
-
34548479249
-
CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment
-
A. Nopp, S.G. Johansson, J. Ankerst, M. Palmqvist, and H. Oman CD-sens and clinical changes during withdrawal of Xolair after 6 years of treatment Allergy 62 2007 1175 1181
-
(2007)
Allergy
, vol.62
, pp. 1175-1181
-
-
Nopp, A.1
Johansson, S.G.2
Ankerst, J.3
Palmqvist, M.4
Oman, H.5
-
10
-
-
33749325937
-
Clinical data do not suggest a causal relationship between omalizumab therapy and cancer
-
C. Fernandez, W. Busse, C. Reisner, and N. Gupta Clinical data do not suggest a causal relationship between omalizumab therapy and cancer Proc Am Thorac Soc 2 2005 A359
-
(2005)
Proc Am Thorac Soc
, vol.2
, pp. 359
-
-
Fernandez, C.1
Busse, W.2
Reisner, C.3
Gupta, N.4
-
11
-
-
0027318539
-
Cancer risk in asthmatic subjects selected from hospital discharge registry
-
B. Kallen, J. Gunnarskog, and T.B. Conradson Cancer risk in asthmatic subjects selected from hospital discharge registry Eur Respir J 6 1993 694 697
-
(1993)
Eur Respir J
, vol.6
, pp. 694-697
-
-
Kallen, B.1
Gunnarskog, J.2
Conradson, T.B.3
-
12
-
-
33745508753
-
Atopic diseases, immunoglobulin e and risk of cancer of the prostate, breast, lung and colorectum
-
H. Wang, D. Rothenbacher, M. Low, C. Stegmaier, H. Brenner, and T.L. Diepgen Atopic diseases, immunoglobulin E and risk of cancer of the prostate, breast, lung and colorectum Int J Cancer 119 2006 695 701
-
(2006)
Int J Cancer
, vol.119
, pp. 695-701
-
-
Wang, H.1
Rothenbacher, D.2
Low, M.3
Stegmaier, C.4
Brenner, H.5
Diepgen, T.L.6
-
13
-
-
0027754111
-
Cancer incidence among 78,000 asthmatic patients
-
E. Vesterinen, E. Pukkala, T. Timonen, and A. Aromaa Cancer incidence among 78,000 asthmatic patients Int J Epidemiol 22 1993 976 982
-
(1993)
Int J Epidemiol
, vol.22
, pp. 976-982
-
-
Vesterinen, E.1
Pukkala, E.2
Timonen, T.3
Aromaa, A.4
-
14
-
-
0028818749
-
A prospective study of cancer incidence in a cohort examined for allergy
-
N.E. Eriksson, A. Holmen, B. Hogstedt, Z. Mikoczy, and L. Hagmar A prospective study of cancer incidence in a cohort examined for allergy Allergy 50 1995 718 722
-
(1995)
Allergy
, vol.50
, pp. 718-722
-
-
Eriksson, N.E.1
Holmen, A.2
Hogstedt, B.3
Mikoczy, Z.4
Hagmar, L.5
-
15
-
-
0026649329
-
Allergy and cancer: Organ site-specific results from the Adventist Health Study
-
P.K. Mills, W.L. Beeson, G.E. Fraser, and R.L. Phillips Allergy and cancer: organ site-specific results from the Adventist Health Study Am J Epidemiol 136 1992 287 295
-
(1992)
Am J Epidemiol
, vol.136
, pp. 287-295
-
-
Mills, P.K.1
Beeson, W.L.2
Fraser, G.E.3
Phillips, R.L.4
-
16
-
-
61749092742
-
Cancer risk in hospitalised asthma patients
-
J. Ji, X. Shu, X. Li, K. Sundquist, J. Sundquist, and K. Hemminki Cancer risk in hospitalised asthma patients Br J Cancer 100 2009 829 833
-
(2009)
Br J Cancer
, vol.100
, pp. 829-833
-
-
Ji, J.1
Shu, X.2
Li, X.3
Sundquist, K.4
Sundquist, J.5
Hemminki, K.6
-
17
-
-
66149147481
-
Safety and tolerability of omalizumab
-
J. Corren, T.B. Casale, B. Lanier, R. Buhl, S. Holgate, and P. Jimenez Safety and tolerability of omalizumab Clin Exp Allergy 39 2009 788 797
-
(2009)
Clin Exp Allergy
, vol.39
, pp. 788-797
-
-
Corren, J.1
Casale, T.B.2
Lanier, B.3
Buhl, R.4
Holgate, S.5
Jimenez, P.6
-
18
-
-
79955406449
-
Safety of omalizumab in asthma
-
R.A. Tan, and J. Corren Safety of omalizumab in asthma Expert Opin Drug Saf 10 2011 463 471
-
(2011)
Expert Opin Drug Saf
, vol.10
, pp. 463-471
-
-
Tan, R.A.1
Corren, J.2
-
19
-
-
70349445071
-
Baseline characteristics of patients enrolled in EXCELS: A cohort study
-
A.A. Long, J.E. Fish, A. Rahmaoui, M.K. Miller, M.S. Bradley, and H.N. Taki Baseline characteristics of patients enrolled in EXCELS: a cohort study Ann Allergy Asthma Immunol 103 2009 212 219
-
(2009)
Ann Allergy Asthma Immunol
, vol.103
, pp. 212-219
-
-
Long, A.A.1
Fish, J.E.2
Rahmaoui, A.3
Miller, M.K.4
Bradley, M.S.5
Taki, H.N.6
-
20
-
-
20044368243
-
The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma
-
J. Bousquet, P. Cabrera, N. Berkman, R. Buhl, S. Holgate, and S. Wenzel The effect of treatment with omalizumab, an anti-IgE antibody, on asthma exacerbations and emergency medical visits in patients with severe persistent asthma Allergy 60 2005 302 308
-
(2005)
Allergy
, vol.60
, pp. 302-308
-
-
Bousquet, J.1
Cabrera, P.2
Berkman, N.3
Buhl, R.4
Holgate, S.5
Wenzel, S.6
-
21
-
-
77952505549
-
Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma
-
M. Kulus, J. Hebert, E. Garcia, T.A. Fowler, V.C. Fernandez, and M. Blogg Omalizumab in children with inadequately controlled severe allergic (IgE-mediated) asthma Curr Med Res Opin 26 2010 1285 1293
-
(2010)
Curr Med Res Opin
, vol.26
, pp. 1285-1293
-
-
Kulus, M.1
Hebert, J.2
Garcia, E.3
Fowler, T.A.4
Fernandez, V.C.5
Blogg, M.6
-
22
-
-
77955663329
-
Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: Real-life data
-
M. Molimard, R. Buhl, R. Niven, V. Le Gros, A. Thielen, and J. Thirlwell Omalizumab reduces oral corticosteroid use in patients with severe allergic asthma: real-life data Respir Med 104 2010 1381 1385
-
(2010)
Respir Med
, vol.104
, pp. 1381-1385
-
-
Molimard, M.1
Buhl, R.2
Niven, R.3
Le Gros, V.4
Thielen, A.5
Thirlwell, J.6
-
23
-
-
71249102935
-
Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma
-
B. Lanier, T. Bridges, M. Kulus, A.F. Taylor, I. Berhane, and C.F. Vidaurre Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma J Allergy Clin Immunol 124 2009 1210 1216
-
(2009)
J Allergy Clin Immunol
, vol.124
, pp. 1210-1216
-
-
Lanier, B.1
Bridges, T.2
Kulus, M.3
Taylor, A.F.4
Berhane, I.5
Vidaurre, C.F.6
-
24
-
-
79953737882
-
Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma
-
J. Bousquet, Z. Siergiejko, E. Swiebocka, M. Humbert, K.F. Rabe, and N. Smith Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma Allergy 66 2011 671 678
-
(2011)
Allergy
, vol.66
, pp. 671-678
-
-
Bousquet, J.1
Siergiejko, Z.2
Swiebocka, E.3
Humbert, M.4
Rabe, K.F.5
Smith, N.6
-
25
-
-
0034881877
-
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics
-
M. Soler, J. Matz, R. Townley, R. Buhl, J. O'Brien, and H. Fox The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics Eur Respir J 18 2001 254 261
-
(2001)
Eur Respir J
, vol.18
, pp. 254-261
-
-
Soler, M.1
Matz, J.2
Townley, R.3
Buhl, R.4
O'Brien, J.5
Fox, H.6
-
26
-
-
79952795093
-
Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children
-
W.W. Busse, W.J. Morgan, P.J. Gergen, H.E. Mitchell, J.E. Gern, and A.H. Liu Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children N Engl J Med 364 2011 1005 1015
-
(2011)
N Engl J Med
, vol.364
, pp. 1005-1015
-
-
Busse, W.W.1
Morgan, W.J.2
Gergen, P.J.3
Mitchell, H.E.4
Gern, J.E.5
Liu, A.H.6
-
27
-
-
79955751312
-
Omalizumab in severe allergic asthma inadequately controlled with standard therapy: A randomized trial
-
N.A. Hanania, O. Alpan, D.L. Hamilos, J.J. Condemi, I. Reyes-Rivera, and J. Zhu Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial Ann Intern Med 154 2011 573 582
-
(2011)
Ann Intern Med
, vol.154
, pp. 573-582
-
-
Hanania, N.A.1
Alpan, O.2
Hamilos, D.L.3
Condemi, J.J.4
Reyes-Rivera, I.5
Zhu, J.6
-
28
-
-
11144356805
-
Efficacy and safety of a recombinant anti-immunoglobulin e antibody (omalizumab) in severe allergic asthma
-
S.T. Holgate, A.G. Chuchalin, J. Hebert, J. Lotvall, G.B. Persson, and K.F. Chung Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma Clin Exp Allergy 34 2004 632 638
-
(2004)
Clin Exp Allergy
, vol.34
, pp. 632-638
-
-
Holgate, S.T.1
Chuchalin, A.G.2
Hebert, J.3
Lotvall, J.4
Persson, G.B.5
Chung, K.F.6
-
29
-
-
20044362008
-
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
-
M. Humbert, R. Beasley, J. Ayres, R. Slavin, J. Hebert, and J. Bousquet Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 60 2005 309 316
-
(2005)
Allergy
, vol.60
, pp. 309-316
-
-
Humbert, M.1
Beasley, R.2
Ayres, J.3
Slavin, R.4
Hebert, J.5
Bousquet, J.6
-
30
-
-
31844443695
-
The environment and disease: Association or causation?
-
A.B. Hill The environment and disease: association or causation? Proc R Soc Med 58 1965 295 300
-
(1965)
Proc R Soc Med
, vol.58
, pp. 295-300
-
-
Hill, A.B.1
-
31
-
-
67651160606
-
The role of causal criteria in causal inferences: Bradford Hill's "aspects of association"
-
A.C. Ward The role of causal criteria in causal inferences: Bradford Hill's "aspects of association" Epidemiol Perspect Innov 6 2009 2
-
(2009)
Epidemiol Perspect Innov
, vol.6
, pp. 2
-
-
Ward, A.C.1
-
32
-
-
33644630456
-
Cancer incidence in a general population of asthma patients
-
A. González-Pérez, C. Fernández-Vidaurre, A. Rueda, E. Rivero, and L.A. García Rodríguez Cancer incidence in a general population of asthma patients Pharmacoepidemiol Drug Saf 15 2006 131 138
-
(2006)
Pharmacoepidemiol Drug Saf
, vol.15
, pp. 131-138
-
-
González-Pérez, A.1
Fernández-Vidaurre, C.2
Rueda, A.3
Rivero, E.4
García Rodríguez, L.A.5
-
33
-
-
0013401756
-
-
National Cancer Institute Available at:. Accessed November 10, 2011
-
National Cancer Institute. Surveillance Epidemiology and End Results. Available at: http://seer.cancer.gov/csr/1975-2008/browse-csr.php?section= 2&page=sect-02-table.07.html. Accessed November 10, 2011.
-
Surveillance Epidemiology and End Results
-
-
-
34
-
-
85058204664
-
Omalizumab and malignancy: Interim results from the EXCELS study
-
M. Eisner, M. Miller, W. Chou, A. Rahmaoui, and M. Bradley Omalizumab and malignancy: interim results from the EXCELS study Eur Respir J 38 suppl 55 2011 A3954
-
(2011)
Eur Respir J
, vol.38
, Issue.SUPPL. 55
, pp. 3954
-
-
Eisner, M.1
Miller, M.2
Chou, W.3
Rahmaoui, A.4
Bradley, M.5
-
35
-
-
0035915364
-
Effect of omalizumab on symptoms of seasonal allergic rhinitis: A randomized controlled trial
-
T.B. Casale, J. Condemi, C. LaForce, A. Nayak, M. Rowe, and M. Watrous Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial JAMA 286 2001 2956 2967
-
(2001)
JAMA
, vol.286
, pp. 2956-2967
-
-
Casale, T.B.1
Condemi, J.2
Laforce, C.3
Nayak, A.4
Rowe, M.5
Watrous, M.6
-
36
-
-
0242606440
-
Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis
-
A. Nayak, T. Casale, S.D. Miller, J. Condemi, M. McAlary, and A. Fowler-Taylor Tolerability of retreatment with omalizumab, a recombinant humanized monoclonal anti-IgE antibody, during a second ragweed pollen season in patients with seasonal allergic rhinitis Allergy Asthma Proc 24 2003 323 329
-
(2003)
Allergy Asthma Proc
, vol.24
, pp. 323-329
-
-
Nayak, A.1
Casale, T.2
Miller, S.D.3
Condemi, J.4
McAlary, M.5
Fowler-Taylor, A.6
-
37
-
-
0033836319
-
Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis
-
E. Ädelroth, S. Rak, T. Haahtela, G. Aasand, L. Rosenhall, and O. Zetterstrom Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis J Allergy Clin Immunol 106 2000 253 259
-
(2000)
J Allergy Clin Immunol
, vol.106
, pp. 253-259
-
-
Ädelroth, E.1
Rak, S.2
Haahtela, T.3
Aasand, G.4
Rosenhall, L.5
Zetterstrom, O.6
-
38
-
-
0034907372
-
Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma
-
W. Busse, J. Corren, B.Q. Lanier, M. McAlary, A. Fowler-Taylor, and G.D. Cioppa Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma J Allergy Clin Immunol 108 2001 184 190
-
(2001)
J Allergy Clin Immunol
, vol.108
, pp. 184-190
-
-
Busse, W.1
Corren, J.2
Lanier, B.Q.3
McAlary, M.4
Fowler-Taylor, A.5
Cioppa, G.D.6
-
39
-
-
0034881877
-
The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics [published erratum appears in Eur Respir J 2001;18:739-40]
-
M. Solr, J. Matz, R. Townley, R. Buhl, J. O'Brien, and H. Fox The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics [published erratum appears in Eur Respir J 2001;18:739-40] Eur Respir J 18 2001 254 261
-
(2001)
Eur Respir J
, vol.18
, pp. 254-261
-
-
Solr, M.1
Matz, J.2
Townley, R.3
Buhl, R.4
O'Brien, J.5
Fox, H.6
-
40
-
-
0035434688
-
Treatment of childhood asthma with anti-immunoglobulin e antibody (omalizumab)
-
E36
-
H. Milgrom, W. Berger, A. Nayak, N. Gupta, S. Pollard, and M. McAlary Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab) Pediatrics 108 2001 E36
-
(2001)
Pediatrics
, vol.108
-
-
Milgrom, H.1
Berger, W.2
Nayak, A.3
Gupta, N.4
Pollard, S.5
McAlary, M.6
-
41
-
-
0043240429
-
Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma
-
W. Berger, N. Gupta, M. McAlary, and A. Fowler-Taylor Evaluation of long-term safety of the anti-IgE antibody, omalizumab, in children with allergic asthma Ann Allergy Asthma Immunol 91 2003 182 188
-
(2003)
Ann Allergy Asthma Immunol
, vol.91
, pp. 182-188
-
-
Berger, W.1
Gupta, N.2
McAlary, M.3
Fowler-Taylor, A.4
-
42
-
-
33645335398
-
Long-term omalizumab therapy is well tolerated in children with moderate-to-severe IgE-mediated asthma (abstract)
-
H. Milgrom, T.P. Miller, B. Lanier, A. Fowler-Taylor, H. Chen, and N. Gupta Long-term omalizumab therapy is well tolerated in children with moderate-to-severe IgE-mediated asthma (abstract) Proc Am Thorac Soc 2 2005 A358
-
(2005)
Proc Am Thorac Soc
, vol.2
, pp. 358
-
-
Milgrom, H.1
Miller, T.P.2
Lanier, B.3
Fowler-Taylor, A.4
Chen, H.5
Gupta, N.6
-
43
-
-
11144356805
-
Efficacy and safety of a recombinant anti-immunoglobulin e antibody (omalizumab) in severe allergic asthma
-
S.T. Holgate, A.G. Chuchalin, J. Hébert, J. Lötvall, G.B. Persson, and K.F. Chung Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma Clin Exp Allergy 34 2004 632 638
-
(2004)
Clin Exp Allergy
, vol.34
, pp. 632-638
-
-
Holgate, S.T.1
Chuchalin, A.G.2
Hébert, J.3
Lötvall, J.4
Persson, G.B.5
Chung, K.F.6
-
44
-
-
66149110204
-
Retreatment with omalizumab, an anti-IgE monoclonal antibody, is well tolerated in patients with severe allergic asthma
-
J. Bousquet, F. Chung, J.M. Tunon-de-Lara, K. Oshinyemi, G. Tran, and H. Fox Retreatment with omalizumab, an anti-IgE monoclonal antibody, is well tolerated in patients with severe allergic asthma Allergy 58 suppl 74 2003 A4
-
(2003)
Allergy
, vol.58
, Issue.SUPPL. 74
, pp. 4
-
-
Bousquet, J.1
Chung, F.2
Tunon-De-Lara, J.M.3
Oshinyemi, K.4
Tran, G.5
Fox, H.6
-
45
-
-
85009292874
-
Long-term safety and tolerability of omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma
-
48S, P421
-
A. Chuchalin, J. Hébert, M. Roli, J. Gao, and C. Reisner Long-term safety and tolerability of omalizumab, an anti-IgE monoclonal antibody, in patients with severe allergic asthma Eur Respir J 26 suppl 49 2005 48S, P421
-
(2005)
Eur Respir J
, vol.26
, Issue.SUPPL. 49
-
-
Chuchalin, A.1
Hébert, J.2
Roli, M.3
Gao, J.4
Reisner, C.5
-
46
-
-
43749098911
-
Omalizumab demonstrates long-term asthma control, safety and tolerability in patients with severe immunoglobulin E-mediated allergic asthma
-
K. Chung, S. Holgate, M. Rolli, J. Gao, and C. Reisner Omalizumab demonstrates long-term asthma control, safety and tolerability in patients with severe immunoglobulin E-mediated allergic asthma Allergy 62 suppl 83 2007 210
-
(2007)
Allergy
, vol.62
, Issue.SUPPL. 83
, pp. 210
-
-
Chung, K.1
Holgate, S.2
Rolli, M.3
Gao, J.4
Reisner, C.5
-
47
-
-
4444232912
-
Effects of treatment with anti-immunoglobulin e antibody omalizumab on airway inflammation in allergic asthma
-
R. Djukanovi, S.J. Wilson, M. Kraft, N.N. Jarjour, M. Steel, and K.F. Chung Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma Am J Respir Crit Care Med 170 2004 583 593
-
(2004)
Am J Respir Crit Care Med
, vol.170
, pp. 583-593
-
-
Djukanovi, R.1
Wilson, S.J.2
Kraft, M.3
Jarjour, N.N.4
Steel, M.5
Chung, K.F.6
-
48
-
-
0041737745
-
Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis
-
P. Chervinsky, T. Casale, R. Townley, I. Tripathy, S. Hedgecock, and A. Fowler-Taylor Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis Ann Allergy Asthma Immunol 91 2003 160 167
-
(2003)
Ann Allergy Asthma Immunol
, vol.91
, pp. 160-167
-
-
Chervinsky, P.1
Casale, T.2
Townley, R.3
Tripathy, I.4
Hedgecock, S.5
Fowler-Taylor, A.6
-
49
-
-
3042786151
-
Efficacy and tolerability of anti-immunoglobulin e therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma
-
J.G. Ayres, B. Higgins, E.R. Chilvers, G. Ayre, M. Blogg, and H. Fox Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma Allergy 59 2004 701 708
-
(2004)
Allergy
, vol.59
, pp. 701-708
-
-
Ayres, J.G.1
Higgins, B.2
Chilvers, E.R.3
Ayre, G.4
Blogg, M.5
Fox, H.6
-
50
-
-
33846464598
-
Safety of anti-immunoglobulin e therapy with omalizumab in allergic patients at risk of geohelminth infection
-
A.A. Cruz, F. Lima, E. Sarinho, G. Ayre, C. Martin, and H. Fox Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection Clin Exp Allergy 37 2007 197 207
-
(2007)
Clin Exp Allergy
, vol.37
, pp. 197-207
-
-
Cruz, A.A.1
Lima, F.2
Sarinho, E.3
Ayre, G.4
Martin, C.5
Fox, H.6
-
51
-
-
3042781547
-
Efficacy and tolerability of anti-immunoglobulin e therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR
-
A.M. Vignola, M. Humbert, J. Bousquet, L.P. Boulet, S. Hedgecock, and M. Blogg Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with concomitant allergic asthma and persistent allergic rhinitis: SOLAR Allergy 59 2004 709 717
-
(2004)
Allergy
, vol.59
, pp. 709-717
-
-
Vignola, A.M.1
Humbert, M.2
Bousquet, J.3
Boulet, L.P.4
Hedgecock, S.5
Blogg, M.6
-
52
-
-
20044362008
-
Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE
-
M. Humbert, R. Beasley, J. Ayres, R. Slavin, J. Hébert, and J. Bousquet Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE Allergy 60 2005 309 316
-
(2005)
Allergy
, vol.60
, pp. 309-316
-
-
Humbert, M.1
Beasley, R.2
Ayres, J.3
Slavin, R.4
Hébert, J.5
Bousquet, J.6
-
53
-
-
71249102935
-
Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma
-
B. Lanier, T. Bridges, M. Kulus, A.F. Taylor, I. Berhane, and C.F. Vidaurre Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma J Allergy Clin Immunol 124 2009 1210 1216
-
(2009)
J Allergy Clin Immunol
, vol.124
, pp. 1210-1216
-
-
Lanier, B.1
Bridges, T.2
Kulus, M.3
Taylor, A.F.4
Berhane, I.5
Vidaurre, C.F.6
-
54
-
-
79953737882
-
Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma
-
J. Bousquet, Z. Siergiejko, E. Swiebocka, M. Humbert, K.F. Rabe, and N. Smith Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma Allergy 66 2011 671 678
-
(2011)
Allergy
, vol.66
, pp. 671-678
-
-
Bousquet, J.1
Siergiejko, Z.2
Swiebocka, E.3
Humbert, M.4
Rabe, K.F.5
Smith, N.6
-
55
-
-
80052389968
-
Bioequivalence of a novel omalizumab solution for injection compared with the standard lyophilized powder formulation
-
G.J. Rivire, C.-M. Yeh, C.V. Reynolds, L. Brookman, and G. Kaiser Bioequivalence of a novel omalizumab solution for injection compared with the standard lyophilized powder formulation J Bioequiv Availab 3 2011 144 150
-
(2011)
J Bioequiv Availab
, vol.3
, pp. 144-150
-
-
Rivire, G.J.1
Yeh, C.-M.2
Reynolds, C.V.3
Brookman, L.4
Kaiser, G.5
-
56
-
-
84871715560
-
High doses of omalizumab (OMA) in patients with allergic (IgE-mediated) asthma and IgE/body weight combinations outside the initially approved dosing table
-
O. Kornmann, H. Watz, C. Munzu, S. Koehne-Voss, V. Erpenback, and G. Kaiser High doses of omalizumab (OMA) in patients with allergic (IgE-mediated) asthma and IgE/body weight combinations outside the initially approved dosing table Eur Respir J 36 suppl 54 2010 P3997
-
(2010)
Eur Respir J
, vol.36
, Issue.SUPPL. 54
, pp. 3997
-
-
Kornmann, O.1
Watz, H.2
Munzu, C.3
Koehne-Voss, S.4
Erpenback, V.5
Kaiser, G.6
-
57
-
-
84862798479
-
Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels
-
S. Zielen, A. Lieb, J. DeMonchy, S. DelaMotte, F. Wagner, and R. Fuhr Omalizumab protects against allergen-induced bronchoconstriction in patients with allergic (IgE-mediated) asthma and high baseline IgE levels Eur Respir J 34 suppl 53 2009 E1869
-
(2009)
Eur Respir J
, vol.34
, Issue.SUPPL. 53
, pp. 1869
-
-
Zielen, S.1
Lieb, A.2
Demonchy, J.3
Delamotte, S.4
Wagner, F.5
Fuhr, R.6
-
58
-
-
84862781676
-
Bioequivalence of a new formulation of omalizumab, solution for injection in prefilled syringe, to the current lyophilized formulation
-
G.J. Rivire, S. Abbi, S. Koehne-Voss, K. Kim, and J.S. Jaffe Bioequivalence of a new formulation of omalizumab, solution for injection in prefilled syringe, to the current lyophilized formulation Eur Respir J 34 suppl 53 2009 E1873
-
(2009)
Eur Respir J
, vol.34
, Issue.SUPPL. 53
, pp. 1873
-
-
Rivire, G.J.1
Abbi, S.2
Koehne-Voss, S.3
Kim, K.4
Jaffe, J.S.5
-
59
-
-
84862805574
-
Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE mediated) asthma
-
L. Somerville, J. Bardelas, A. Viegas, P. D'Andrea, J. Thirlwell, and M. Massanari Evaluation of the immunogenicity and safety of a new formulation of omalizumab (solution for injection) in patients with allergic (IgE mediated) asthma Eur Respir J 34 suppl 53 2009 E1876
-
(2009)
Eur Respir J
, vol.34
, Issue.SUPPL. 53
, pp. 1876
-
-
Somerville, L.1
Bardelas, J.2
Viegas, A.3
D'Andrea, P.4
Thirlwell, J.5
Massanari, M.6
-
60
-
-
33846084882
-
Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis
-
K. Okubo, S. Ogino, T. Nagakura, and T. Ishikawa Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis Allergol Int 55 2006 379 386
-
(2006)
Allergol Int
, vol.55
, pp. 379-386
-
-
Okubo, K.1
Ogino, S.2
Nagakura, T.3
Ishikawa, T.4
-
61
-
-
70350444881
-
Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma
-
K. Ohta, T. Miyamoto, T. Amagasaki, and M. Yamamoto Efficacy and safety of omalizumab in an Asian population with moderate-to-severe persistent asthma Respirology 14 2009 1156 1165
-
(2009)
Respirology
, vol.14
, pp. 1156-1165
-
-
Ohta, K.1
Miyamoto, T.2
Amagasaki, T.3
Yamamoto, M.4
-
62
-
-
38349133719
-
Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis
-
T. Nagakura, S. Ogino, K. Okubo, N. Sato, M. Takahashi, and T. Ishikawa Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis Clin Exp Allergy 38 2008 329 337
-
(2008)
Clin Exp Allergy
, vol.38
, pp. 329-337
-
-
Nagakura, T.1
Ogino, S.2
Okubo, K.3
Sato, N.4
Takahashi, M.5
Ishikawa, T.6
-
63
-
-
77954561297
-
One year treatment with omalizumab is effective and well tolerated in Japanese patients with moderate-to-severe persistent asthma
-
K. Ohta, M. Yamamoto, N. Sato, K. Ikeda, and T. Miyamoto One year treatment with omalizumab is effective and well tolerated in Japanese patients with moderate-to-severe persistent asthma Allergol Int 2 2010 167 174
-
(2010)
Allergol Int
, vol.2
, pp. 167-174
-
-
Ohta, K.1
Yamamoto, M.2
Sato, N.3
Ikeda, K.4
Miyamoto, T.5
-
64
-
-
0036174045
-
Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis
-
J. Kuehr, J. Brauburger, S. Zielen, U. Schauer, W. Kamin, and A. Von Berg Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis J Allergy Clin Immunol 109 2002 274 280
-
(2002)
J Allergy Clin Immunol
, vol.109
, pp. 274-280
-
-
Kuehr, J.1
Brauburger, J.2
Zielen, S.3
Schauer, U.4
Kamin, W.5
Von Berg, A.6
-
65
-
-
58849143492
-
Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma
-
M.V. Kopp, E. Hamelmann, S. Zielen, W. Kamin, K.C. Bergmann, and C. Sieder Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma Clin Exp Allergy 39 2009 271 279
-
(2009)
Clin Exp Allergy
, vol.39
, pp. 271-279
-
-
Kopp, M.V.1
Hamelmann, E.2
Zielen, S.3
Kamin, W.4
Bergmann, K.C.5
Sieder, C.6
-
66
-
-
79959855552
-
Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase
-
M. Maurer, S. Altrichter, T. Bieber, T. Biedermann, M. Brautigam, and S. Seyfried Efficacy and safety of omalizumab in patients with chronic urticaria who exhibit IgE against thyroperoxidase J Allergy Clin Immunol 128 2011 202 209
-
(2011)
J Allergy Clin Immunol
, vol.128
, pp. 202-209
-
-
Maurer, M.1
Altrichter, S.2
Bieber, T.3
Biedermann, T.4
Brautigam, M.5
Seyfried, S.6
-
67
-
-
1142297324
-
Effect of omalizumab in health care workers with occupational latex allergy
-
F. Leynadier, O. Doudou, H. Gaouar, V. Le Gros, I. Bourdeix, and L. Guyomarch-Cocco Effect of omalizumab in health care workers with occupational latex allergy J Allergy Clin Immunol 113 2004 360 361
-
(2004)
J Allergy Clin Immunol
, vol.113
, pp. 360-361
-
-
Leynadier, F.1
Doudou, O.2
Gaouar, H.3
Le Gros, V.4
Bourdeix, I.5
Guyomarch-Cocco, L.6
-
68
-
-
77957168146
-
Omalizumab-induced decrease of FcεRI expression in patients with severe allergic asthma
-
P. Chanez, C. Contin-Bordes, G. Garcia, C. Verkindre, A. Didier, and F. De Blay Omalizumab-induced decrease of FcεRI expression in patients with severe allergic asthma Respir Med 104 2010 1608 1617
-
(2010)
Respir Med
, vol.104
, pp. 1608-1617
-
-
Chanez, P.1
Contin-Bordes, C.2
Garcia, G.3
Verkindre, C.4
Didier, A.5
De Blay, F.6
-
69
-
-
75849151415
-
Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma
-
M. Massanari, H. Nelson, T. Casale, W. Busse, F. Kianifard, and G.P. Geba Effect of pretreatment with omalizumab on the tolerability of specific immunotherapy in allergic asthma J Allergy Clin Immunol 125 2010 383 389
-
(2010)
J Allergy Clin Immunol
, vol.125
, pp. 383-389
-
-
Massanari, M.1
Nelson, H.2
Casale, T.3
Busse, W.4
Kianifard, F.5
Geba, G.P.6
-
70
-
-
0030853854
-
Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis
-
T.B. Casale, I.L. Bernstein, W.W. Busse, C.F. LaForce, D.G. Tinkelman, and R.R. Stoltz Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis J Allergy Clin Immunol 100 1997 110 121
-
(1997)
J Allergy Clin Immunol
, vol.100
, pp. 110-121
-
-
Casale, T.B.1
Bernstein, I.L.2
Busse, W.W.3
Laforce, C.F.4
Tinkelman, D.G.5
Stoltz, R.R.6
-
71
-
-
8244226656
-
Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response
-
L.P. Boulet, K.R. Chapman, J. Côté, S. Kalra, R. Bhagat, and V.A. Swystun Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response Am J Respir Crit Care Med 155 1997 1835 1840
-
(1997)
Am J Respir Crit Care Med
, vol.155
, pp. 1835-1840
-
-
Boulet, L.P.1
Chapman, K.R.2
Côté, J.3
Kalra, S.4
Bhagat, R.5
Swystun, V.A.6
-
72
-
-
0030956903
-
The effect of an anti-IgE monoclonal antibody on the early- and late- phase responses to allergen inhalation in asthmatic subjects
-
J.V. Fahy, H.E. Fleming, H.H. Wong, J.T. Liu, J.Q. Su, and J. Reimann The effect of an anti-IgE monoclonal antibody on the early- and late- phase responses to allergen inhalation in asthmatic subjects Am J Respir Crit Care Med 155 1997 1828 1834
-
(1997)
Am J Respir Crit Care Med
, vol.155
, pp. 1828-1834
-
-
Fahy, J.V.1
Fleming, H.E.2
Wong, H.H.3
Liu, J.T.4
Su, J.Q.5
Reimann, J.6
-
73
-
-
0000746848
-
Phase i study of anti-IgE recombinant humanized monoclonal antibody rhuMAB-E25 (E25) in adults with moderate to severe asthma [abstract]
-
J. Corren, J. Froehlich, J. Schoenhoff, S. Spector, G. Rachelefsky, and H. Schanker Phase I study of anti-IgE recombinant humanized monoclonal antibody rhuMAB-E25 (E25) in adults with moderate to severe asthma [abstract] J Allergy Clin Immunol 97 suppl 1996 245
-
(1996)
J Allergy Clin Immunol
, vol.97
, Issue.SUPPL.
, pp. 245
-
-
Corren, J.1
Froehlich, J.2
Schoenhoff, J.3
Spector, S.4
Rachelefsky, G.5
Schanker, H.6
-
74
-
-
0033136728
-
Down-regulation of human basophil IgE and FC-epsilon-RI-alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo
-
S.S. Saini, D.W. MacGlashan, S.A. Sterbinsky, A. Togias, D.C. Adelman, and L.M. Lichtenstein Down-regulation of human basophil IgE and FC-epsilon-RI-alpha surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo J Immunol 162 1999 5624 5630
-
(1999)
J Immunol
, vol.162
, pp. 5624-5630
-
-
Saini, S.S.1
MacGlashan, D.W.2
Sterbinsky, S.A.3
Togias, A.4
Adelman, D.C.5
Lichtenstein, L.M.6
-
75
-
-
0033599043
-
Treatment of allergic asthma with monoclonal anti-IgE antibody
-
H. Milgrom, R.B. Fick, J.Q. Su, J.D. Reimann, R.K. Bush, and M.L. Watrous Treatment of allergic asthma with monoclonal anti-IgE antibody N Engl J Med 341 1999 1966 1973
-
(1999)
N Engl J Med
, vol.341
, pp. 1966-1973
-
-
Milgrom, H.1
Fick, R.B.2
Su, J.Q.3
Reimann, J.D.4
Bush, R.K.5
Watrous, M.L.6
-
76
-
-
79952303048
-
A phase II, randomized, double blind, parallel group, placebo controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy
-
H.A. Sampson, D.Y.M. Leung, A.W. Burks, G. Lack, S.L. Bahna, and S.M. Jones A phase II, randomized, double blind, parallel group, placebo controlled oral food challenge trial of Xolair (omalizumab) in peanut allergy J Allergy Clin Immunol 127 2011 1309 1310
-
(2011)
J Allergy Clin Immunol
, vol.127
, pp. 1309-1310
-
-
Sampson, H.A.1
Leung, D.Y.M.2
Burks, A.W.3
Lack, G.4
Bahna, S.L.5
Jones, S.M.6
-
77
-
-
79955751312
-
Omalizumab in severe allergic asthma inadequately controlled with standard therapy - A randomized trial
-
N.A. Hanania, O. Alpan, D.L. Hamilos, J.J. Condemi, I. Reyes-Rivera, and J. Zhu Omalizumab in severe allergic asthma inadequately controlled with standard therapy - a randomized trial Ann Intern Med 154 2011 573 582
-
(2011)
Ann Intern Med
, vol.154
, pp. 573-582
-
-
Hanania, N.A.1
Alpan, O.2
Hamilos, D.L.3
Condemi, J.J.4
Reyes-Rivera, I.5
Zhu, J.6
-
78
-
-
79551483914
-
Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge
-
J. Corren, R.A. Wood, D. Patel, J. Zhu, A. Yegin, and G. Dhillon Effects of omalizumab on changes in pulmonary function induced by controlled cat room challenge J Allergy Clin Immunol 127 2011 398 405
-
(2011)
J Allergy Clin Immunol
, vol.127
, pp. 398-405
-
-
Corren, J.1
Wood, R.A.2
Patel, D.3
Zhu, J.4
Yegin, A.5
Dhillon, G.6
-
79
-
-
80052299857
-
A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria
-
e1
-
S. Saini, K.E. Rosen, H.J. Hsieh, D.A. Wong, E. Conner, and A. Kaplan A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria J Allergy Clin Immunol 128 2011 567 573 e1
-
(2011)
J Allergy Clin Immunol
, vol.128
, pp. 567-573
-
-
Saini, S.1
Rosen, K.E.2
Hsieh, H.J.3
Wong, D.A.4
Conner, E.5
Kaplan, A.6
|